<DOC>
	<DOCNO>NCT00408213</DOCNO>
	<brief_summary>This 2 arm study provide optional continuation double-blind treatment CellCept placebo , patient myasthenia gravis achieve good symptom control study WX17798 . Patients complete 36 week treatment study WX17798 , stable prednisone dose last 4 week , continue blind treatment CellCept ( 1g bid ) placebo database WX17798 lock unblinded . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Continuation Study Assess Effect CellCept Patients With Myasthenia Gravis .</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>subject complete 36 week treatment study WX17798 , demonstrate good symptom control stable prednisone dose final 4 week study . regularly schedule plasma exchange intravenous immunoglobulin treatment ; medical condition , adverse event intolerance doubleblind treatment would preclude continuation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>